OQROGet OQRO Pro
Insider trade

Merck (MRK)Officer sold ~$512K

David Michael Williams, Officer at Merck, sold ~$512K of Merck shares.

~$512K
Approx. value · 6,000 sh @ $85.34
24K
Holds after · shares reported
Traded
Feb 13, 2025
Filed
Feb 13, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 15, 2025Congress · 1 personMembers of Congress: 3 sales
  2. Jan 16, 2025Congress · 1 personMembers of Congress: 2 sales
  3. Jan 17, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  4. Jan 24, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  5. Jan 27, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  6. Jan 28, 2025FDAFDA drug approval: Keytruda
  7. Feb 5, 2025InsiderDirector purchased ~$1.33M of MRK shares in the open market
  8. Feb 6, 2025Insider · 2 peopleInsiders: 1 purchase (~$250K), 1 sale (~$210K)
  9. Feb 12, 2025Court · District Court, D. New JerseySecurities lawsuit filed: IN RE MERCK & CO., INC. SECURITIES LITIGATION
  10. Feb 13, 2025 · this disclosureInsiderOfficer sold ~$512K of MRK shares in the open market

What came next

  1. Feb 19, 2025InsiderOfficer sold ~$715K of MRK shares in the open market
  2. Feb 24, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
  3. Feb 25, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  4. Feb 26, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
  5. Mar 3, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  6. Mar 19, 2025FDAFDA drug approval: Keytruda
  7. Mar 20, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  8. Mar 31, 2025CongressDisclosed partial sale of MRK — reported range $15,001 - $50,000
  9. Apr 8, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
  10. Apr 9, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  11. Apr 15, 2025FDAFDA drug approval: Welireg
  12. Apr 15, 2025FDAFDA drug approval: Welireg
  13. Apr 17, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  14. Apr 21, 2025FDAFDA drug approval: Keytruda
  15. Apr 21, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  16. Apr 25, 2025InsiderOfficer sold ~$353K of MRK shares in the open market
  17. Apr 29, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  18. May 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  19. May 14, 2025FDAFDA drug approval: Welireg
  20. May 15, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 123 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by David Michael Williams, EVP,Chief Info&Digital Officer

The full history of David Michael Williams, EVP,Chief Info&Digital Officer is on the profile page.

How this filing works

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data